florbetaben F-18
Trade name: neuraceq
Approved
Mar 19, 2014
Florbetaben F18 is a18F-labeled stilbene derivative used as a tracer for PET imaging of beta-amyloid deposits in the human brain. The F 18 isotope produces a positron signal that is detected by a PET scanner. 3H-florbetaben in vitro binding experiments reveal two binding sites (Kd of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F18 to beta-amyloid plaques in post-mortem brain sections from patients with AD using autoradiography correlates with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 does not bind to tau or alpha-synuclein in tissue from patients with AD. Neither Neuraceq nor non-radioactive florbetaben F 19 bind to AT8 positive tau deposits in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively. — NCATS
Clinical trial activity
24 trials · 17 clinical orgs · 1 marketing orgs
Earliest trial started Jun 1, 2008 (NCT01138111)
Timeline
Indications
Approved for
Mechanism of action
- Amyloid beta A4 proteinBINDING AGENT
APP binding agent
Approval history
- approvedMar 19, 2014
Chemistry & pharmacology
SMILES
CNc1ccc(/C=C/c2ccc(OCCOCCOCCF)cc2)cc1- Mol. weight
- 359.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1908906 ↗
- WikipediaFlorbetaben (18F) ↗
- NCATSTLA7312TOI ↗
- ChEMBLCHEMBL566752 ↗
Also known as
- 18f-bay94-9172
- [18f]florbetaben
- [18f]florbetaben
- 18f-florbetaben
- 18f-florbetaben
- 18f-florbetaben
- 4-(n-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
- bay 94-9172
- bay-949172
- bay-949172
- bay94 9172
- bay94-9172
- florbetaben
- florbetaben
- florbetaben
- florbetaben
- florbetaben (18f)
- florbetaben (18f)
- florbetaben (18f)
- florbetaben (18f)
- florbetaben (18f)
- florbetaben f18
- florbetaben f18
- florbetaben f18
- florbetaben f18
- florbetaben f-18
- florbetaben f-18
- florbetaben f-18
- florbetaben f-18
- florbetaben f-18
- florbetaben f18 injection
- neuraceq
- neuraceq
- neuraceq
- neuraceq
- unii-tla7312toi
- unii-tla7312toi
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07169630 | Phase 1 | Dec 2, 2025 | National Institute of Mental Health (NIMH) |
| NCT05184088 | Phase 3 | Jan 31, 2023 | pharmtrace klinische Entwicklung GmbH, Piramal |
| NCT05504200 | N/A | Mar 16, 2022 | Royal National Orthopaedic Hospital NHS Trust |
| NCT05361382 | Phase 1 | Nov 23, 2021 | National Institute on Aging (NIA), University of Pittsburgh |
| NCT05527288 | N/A | Jan 28, 2021 | Sinotau Pharmaceutical Group |
| NCT04576793 | Phase 2 | Nov 1, 2020 | Columbia University, National Institute on Aging (NIA) |
| NCT04392960 | N/A | Jun 30, 2020 | University of Pavia |
| NCT04105634 | Early Phase 1 (Phase 1) | Oct 1, 2019 | University of Pennsylvania |
| NCT03616496 | Phase 2/Phase 3 (Phase 3) | Jun 4, 2019 | University of Lorraine |
| NCT03706261 | Phase 1 | Mar 22, 2019 | Columbia University, National Institute on Aging (NIA) |
| NCT03744312 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2018 | Columbia University |
| NCT03779815 | N/A | Aug 20, 2018 | University of Ulsan |
| NCT03057938 | Phase 2 | Mar 15, 2017 | University of Barcelona |
| NCT02664571 | N/A | Mar 1, 2017 | Centre Hospitalier Universitaire de Nīmes |
| NCT02831283 | Phase 2 | Jun 1, 2016 | Columbia University, National Institute on Aging (NIA) |
| NCT03119558 | Early Phase 1 (Phase 1) | May 26, 2016 | Stanford University |
| NCT02669225 | Early Phase 1 (Phase 1) | Jan 20, 2016 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT02681172 | Phase 4 | Oct 1, 2015 | Piramal |
| NCT02362880 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2015 | University of Barcelona |
| NCT01222351 | N/A | Dec 1, 2010 | Bayer, Columbia University, National Institute on Aging (NIA) |
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Piramal | For profit | 6 | 6 | 4 | 2008 |
| Columbia University | Academic/Hospital | 5 | 5 | 3 | 2010 |
| National Institute on Aging (NIA) | Government | 5 | 0 | 3 | 2010 |
| Bayer | For profit | 4 | 0 | 3 | 2008 |
| University of Barcelona | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Centre Hospitalier Universitaire de Nīmes | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2025 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2016 |
| pharmtrace klinische Entwicklung GmbH | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Royal National Orthopaedic Hospital NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Sinotau Pharmaceutical Group | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Lorraine | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Pavia | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2018 |